ONC:NASDAQ
BeOne Medicines AG
350,84 $
arrow_downward
-0,74%(-2,62) 1D
350,84 $
0,00% (0,00)
todayPre-market
Closed: 18 қыр., 16:00:01 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
352,13 $
High
354,04 $
Low
348,76 $
Mkt. cap
43,07 млрд
Avg. vol.
391,81 м.
Volume
5,81 мың
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 мың
Open
352,13 $
High
354,04 $
Low
348,76 $
Mkt. cap
43,07 млрд
Avg. vol.
391,81 м.
Volume
5,81 мың
52-wk high
385,22 $
52-wk low
253,95 $
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 мың
News stories
From web sources and news partners
AD HOC NEWS
·
1 күн бұрын
BeiGene stock holds steady as investors digest recent quarterly losses
careplusvn.com
·
2 ай бұрын
BeOne Medicines (ONC) Dips 1.7% as Shares Retreat from Resistance Zone - Collar Trade
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 мың
Founded2010 ж. 28 қаз.
Headquarters-
Sector-
Websitebeonemedicines.com